US20260130852
2026-05-14
Human necessities
A61K9/1075
The biphasic nutraceutical system is designed to enhance the bioavailability of bioactive compounds by aligning their delivery with the body's circadian rhythms. It consists of two formulations: a daytime one that supports metabolic activation and cognitive readiness, and a nighttime one that aids nutritional regeneration and immune balance. The active compounds are encapsulated for specific delivery, using phospholipid-stabilized micellar vesicles for sublingual uptake during the day and pH-sensitive polysaccharide hydrogel matrices for delayed absorption at night. This system aims to synchronize nutrient absorption with the body's natural physiological cycles without relying on pharmacological methods.
The invention falls within the realm of biotechnology and nutraceutical delivery systems, focusing on the circadian alignment of bioactive compound administration. Unlike previous systems that do not consider timing-specific bioavailability, this dual-phase approach integrates encapsulation strategies with phospholipid micelles for daytime and polysaccharide nanoparticles for nighttime. These innovations differentiate the system from existing technologies by offering a structured, timing-controlled nutrient release mechanism.
The system's efficiency has been validated through various non-clinical tests, including in vitro and ex vivo studies, as well as computational modeling. Results demonstrated a significant increase in nutrient uptake and reduced enzymatic degradation, confirming improved bioactive assimilation and integrity during digestive transit. Dynamic simulations also showed a biphasic absorption profile, with nutrient availability peaking at specific times for both phases, aligning with metabolic windows.
The nutraceutical system employs a method of circadian-aligned biphasic administration. The first phase involves a morning composition with antioxidant adaptogens and phospholipid cofactors, administered shortly after waking. The second phase consists of regenerative bioactives in polysaccharide nanoparticles, taken in the evening. The timing and dosage are modulated through a non-therapeutic algorithm that aligns with physiological patterns, using formats like time-release capsules or gastro-resistant coatings.
Both compositions are formulated using GRAS-recognized compounds and comply with regulatory standards such as U.S. GRAS, EU Novel Food Regulation, and Canada's NHP classification. The system is adaptable, allowing for personalization based on demographic and physiological factors. It supports modular implementation across user populations, with claim protection covering various delivery formats and biometric modulation techniques.